Retraction Note: Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a (Scientific Reports, (2015), 5, 1, (9787), 10.1038/srep09787);Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhang, Shun ^a   Chen, Ping ^a   Huang, Zuoan ^a   Hu, Xiaorong ^a   Chen, Mengting ^b   Hu, Shanshan ^b   Hu, Yixin ^b   Cai, Ting ^a  

^a NINGBO NO 2 HOSPITAL   (China)

^b NINGBO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRN34 MICRORNA, HUMAN; SIRT7 PROTEIN, HUMAN; SIRTUIN;

ADULT; AGED; APOPTOSIS; CANCER STAGING; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME;

ADULT; AGED; APOPTOSIS; CELL LINE, TUMOR; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; SIRTUINS; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84928036633     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-023-37359-8     Document Type: Erratum

References (30)

1. Toyota, M. et al.AberrantMethylation in Gastric Cancer Associated with the CpG Island Methylator Phenotype. Cancer Res. 59, 5438-5442 (1999).
2. Satoh, A. et al. Epigenetic Inactivation of CHFR and Sensitivity to Microtubule Inhibitors in Gastric Cancer. Cancer Res. 63, 8606-8613 (2003).
3. Sato, K. et al. Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer. Virchows Arch. 440, 160-165, doi:10.1007/s004280100499 (2002).
4. Kim, T. Y. et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab. Invest. 84, 479-484, doi:10.1038/labinvest.3700060 (2004).
5. Shen, R., Pan, S., Qi, S., Lin, X. & Cheng, S. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem. Biophys. Res. Commun. 394, 1047-1052, doi:http://dx.doi.org/10.1016/j.bbrc.2010.03.121 (2010).
6. Suzuki, H. et al. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis 31, 2066-2073, doi:10.1093/carcin/bgq203 (2010).
7. Hashimoto, Y., Akiyama, Y., Otsubo, T., Shimada, S. & Yuasa, Y. Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis 31, 777-784, doi:10.1093/carcin/bgq013 (2010).
8. Matsukawa, Y. et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 97, 484-491, doi:10.1111/j.1349-7006.2006.00203.x (2006).
9. Park, Y. et al. The Global Histone Modification Pattern Correlates with Cancer Recurrence and Overall Survival in Gastric Adenocarcinoma. Ann. Surg. Oncol. 15, 1968-1976, doi:10.1245/s10434-008-9927-9 (2008).
10. Imai, S. I. & Guarente, L. NAD and sirtuins in aging and disease. Trends Cell Biol. 24, 464-471, doi:10.1016/j.tcb.2014.04.002 (2014).
11. Roth, M. & Chen,W. Y. Sorting out functions of sirtuins in cancer. Oncogene 33, 1609-1620, doi:10.1038/onc.2013.120 (2014).
12. Barber, M. F. et al. SIRT7 links H3K18 deacetylation tomaintenance of oncogenic transformation. Nature 487, 114-118, doi:10.1038/nature11043 (2012).
13. Wadhwa, R. et al. Gastric cancer-molecular and clinical dimensions. Nat. Rev. Clin. Oncol. 10, 643-655, doi:10.1038/nrclinonc.2013.170 (2013).
14. Suzuki, H. et al. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis 31, 2066-2073, doi:10.1093/carcin/bgq203 (2010).
15. Tsai, K.-W. et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int. J. Cancer 129, 2600-2610, doi:10.1002/ijc.25919 (2011).
16. Cha, E. J. et al . Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin. Cancer. Res. 15, 4453-4459, doi:10.1158/1078-0432. CCR-08-3329 (2009).
17. Cao, Z. et al . Genetic and Expression Analysis of the SIRT1 Gene in Gastric Cancers. J. Gastric Cancer 10, 91-98 (2010).
18. Kim, Y. R., Kim, S. S., Yoo, N. J. & Lee, S. H. Frameshift mutation of SIRT1 gene in gastric and colorectal carcinomas with microsatellite instability. APMIS 118, 81-82, doi:10.1111/j.1600-0463.2009.02560.x (2010).
19. Zhu, H. et al. Activating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRT1 expression. PLoS One 7, e31431, doi:10.1371/journal.pone.0031431 (2012).
20. Li, H. J. et al . Diet-induced obesity promotes murine gastric cancer growth through a nampt/sirt1/c-myc positive feedback loop. Oncol. Rep., doi:10.3892/or.2013.2678 (2013).
21. Vakhrusheva, O. et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ. Res. 102, 703-710, doi:10.1161/CIRCRESAHA.107.164558 (2008).
22. Michishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C. & Horikawa, I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell 16, 4623-4635, doi:10.1091/mbc.E05-01-0033 (2005).
23. Yamakuchi, M. & Lowenstein, C. J. MiR-34, SIRT1, and p53: The feedback loop. Cell Cycle 8, 712-715 (2009).
24. Osawa, S. et al.MicroRNA profiling of gastric cancer patients from formalin-fixed paraffin-embedded samples. Oncol. Lett. 2, 613-619, doi:10.3892/ol.2011.313 (2011).
25. Stánitz, É. et al. Evaluation of MicroRNA Expression Pattern of Gastric Adenocarcinoma Associated with Socioeconomic, Environmental and Lifestyle Factors in Northwestern Hungary. Anticancer Res. 33, 3195-3200 (2013).
26. Cao, W. et al. Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells. Tumor Biol. 34, 963-971, doi:10.1007/s13277-012-0632-8 (2013).
27. Scognamiglio, I. et al. Transferrin-conjugated SNALPs encapsulating 2′-O-methylated miR-34a for the treatment of multiple myeloma. BioMed research international 2014, 217365, doi:10.1155/2014/217365 (2014).
28. Di Martino, M. T. et al. In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One 9, e90005, doi:10.1371/journal.pone.0090005 (2014).
29. Misso, G. et al. Mir-34: a new weapon against cancer? Molecular therapy. Nucleic acids 3, e194, doi:10.1038/mtna.2014.47 (2014).
30. Chang, T. C. et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26, 745-752, doi:10.1016/j. molcel.2007.05.010 (2007).